Niaspan inhibits diabetic retinopathy‑induced vascular inflammation by downregulating the tumor necrosis factor‑α pathway

Wang,Yang; Meng,Xiangda; Yan,Hua

doi:10.3892/mmr.2017.6146

Niaspan inhibits diabetic retinopathy‑induced vascular inflammation by downregulating the tumor necrosis factor‑α pathway

Authors:
- Yang Wang
- Xiangda Meng
- Hua Yan
View Affiliations

Affiliations: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China
Published online on: January 25, 2017 https://doi.org/10.3892/mmr.2017.6146
Pages: 1263-1271
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic retinopathy (DR) is a serious microvascular complication of diabetes and a major cause of blindness in the developing world. Early DR is characterized by vascular neuroinflammation, cell apoptosis and breakdown of the blood‑retinal barrier (BRB). However, optimal treatment options and associated mechanisms remain unclear. Niaspan, which is widely used in the prevention and treatment of hyperlipidemia‑associated diseases, has been reported to inhibit inflammation. However, the effects of Niaspan and the mechanisms underlying the anti‑inflammatory effects of Niaspan on DR have yet to be reported. The present study aimed to investigate the anti‑inflammatory effects and mechanisms of Niaspan in a rat model of DR. Rats with DR exhibited a significant increase in BRB breakdown, retinal apoptosis, and tumor necrosis factor‑α (TNF‑α) and nuclear factor‑κB (NF‑κB) expression. In addition, the expression levels of inducible nitric oxide synthase (iNOS) and intercellular cell adhesion molecule‑1 (ICAM‑1) were increased in the retinas of DR rats compared with in the normal control group. In conclusion, treatment with Niaspan significantly improved clinical and histopathological outcomes; decreased the expression levels of TNF‑α, NF‑κB, iNOS and ICAM‑1; and decreased apoptosis and BRB breakdown, as compared with in the retinas of DR rats. The present study is the first, to the best of our knowledge, to demonstrate that Niaspan treatment ameliorates DR by inhibiting inflammation, and also suggests that the TNF‑α pathway may contribute to the beneficial effects of Niaspan treatment.

View Figures

View References

1	Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL III and Klein R: Diabetic retinopathy. Diabetes Care. 21:143–156. 1998. View Article : Google Scholar : PubMed/NCBI
2	Stem MS and Gardner TW: Neurodegeneration in the pathogenesis of diabetic retinopathy: Molecular mechanisms and therapeutic implications. Curr Med Chem. 20:3241–3250. 2013. View Article : Google Scholar : PubMed/NCBI
3	Abcouwer SF: Angiogenic factors and cytokines in diabetic retinopathy. J Clin Cell Immunol. (Suppl 1). 2013.PubMed/NCBI
4	Chapman MJ, Assmann G, Fruchart JC, Shepherd J and Sirtori C: European Consensus Panel on HDL-C: Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: The role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin. 20:1253–1268. 2004. View Article : Google Scholar : PubMed/NCBI
5	Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS and Brinton EA: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA. 284:1263–1270. 2000. View Article : Google Scholar : PubMed/NCBI
6	Heemskerk MM, Dharuri HK, van den Berg SA, Jónasdóttir HS, Kloos DP, Giera M, van Dijk KW and van Harmelen V: Prolonged niacin treatment leads to increased adipose tissue PUFA synthesis and anti-inflammatory lipid and oxylipin plasma profile. J Lipid Res. 55:2532–2540. 2014. View Article : Google Scholar : PubMed/NCBI
7	Si Y, Zhang Y, Zhao J, Guo S, Zhai L, Yao S, Sang H, Yang N, Song G, Gu J and Qin S: Niacin inhibits vascular inflammation via downregulating nuclear transcription factor-κB signaling pathway. Mediators Inflamm. 2014:2637862014. View Article : Google Scholar : PubMed/NCBI
8	Zhang W and Yan H: Simvastatin increases circulating endothelial progenitor cells and reduces the formation and progression of diabetic retinopathy in rats. Exp Eye Res. 105:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
9	Lei S, Li H, Xu J, Liu Y, Gao X, Wang J, Ng KF, Lau WB, Ma XL, Rodrigues B, et al: Hyperglycemia-induced protein kinase C β2 activation induces diastolic cardiac dysfunction in diabetic rats by impairing caveolin-3 expression and Akt/eNOS signaling. Diabetes. 62:2318–2328. 2013. View Article : Google Scholar : PubMed/NCBI
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C (T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Arden GB and Sivaprasad S: The pathogenesis of early retinal changes of diabetic retinopathy. Doc Ophthalmol. 124:15–26. 2012. View Article : Google Scholar : PubMed/NCBI
12	Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG and Gardner TW: Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 102:783–791. 1998. View Article : Google Scholar : PubMed/NCBI
13	Joussen AM, Doehmen S, Le ML, Koizumi K, Radetzky S, Krohne TU, Poulaki V, Semkova I and Kociok N: TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis. 15:1418–1428. 2009.PubMed/NCBI
14	Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, et al: A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 18:1450–1452. 2004.PubMed/NCBI
15	Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW and Levison SW: Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 54:1559–1565. 2005. View Article : Google Scholar : PubMed/NCBI
16	Mukhopadhyay S, Hoidal JR and Mukherjee TK: Role of TNFalpha in pulmonary pathophysiology. Respir Res. 7:1252006. View Article : Google Scholar : PubMed/NCBI
17	el Abu Asrar AM, Maimone D, Morse PH, Gregory S and Reder AT: Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol. 114:731–736. 1992. View Article : Google Scholar : PubMed/NCBI
18	Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Döhmen S and Adamis AP: Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 16:438–440. 2002.PubMed/NCBI
19	Vinores SA, Xiao WH, Shen J and Campochiaro PA: TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J Neuroimmunol. 182:73–79. 2007. View Article : Google Scholar : PubMed/NCBI
20	Jiang Y, Zhang Q, Soderland C and Steinle JJ: TNFα and SOCS3 regulate IRS-1 to increase retinal endothelial cell apoptosis. Cell Signal. 24:1086–1092. 2012. View Article : Google Scholar : PubMed/NCBI
21	Sun X, Han F, Yi J, Han L and Wang B: Effect of aspirin on the expression of hepatocyte NF-κB and serum TNF-α in streptozotocin-induced type 2 diabetic rats. J Korean Med Sci. 26:765–770. 2011. View Article : Google Scholar : PubMed/NCBI
22	Takeda K, Kermani P, Anastasia A, Obinata Y, Hempstead BL and Kurihara H: BDNF protects human vascular endothelial cells from TNFα-induced apoptosis. Biochem Cell Biol. 91:341–349. 2013. View Article : Google Scholar : PubMed/NCBI
23	Gao JJ, Hu YW, Wang YC, Sha YH, Ma X, Li SF, Zhao JY, Lu JB, Huang C, Zhao JJ, et al: ApoM suppresses TNF-α-induced expression of ICAM-1 and VCAM-1 through inhibiting the activity of NF-κB. DNA Cell Biol. 34:550–556. 2015. View Article : Google Scholar : PubMed/NCBI
24	Kern TS: Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007:951032007. View Article : Google Scholar : PubMed/NCBI
25	Ellis EA, Guberski DL, Hutson B and Grant MB: Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/WOR rat. Nitric Oxide. 6:295–304. 2002. View Article : Google Scholar : PubMed/NCBI
26	El-Asrar Abu AM, Desmet S, Meersschaert A, Dralands L, Missotten L and Geboes K: Expression of the inducible isoform of nitric oxide synthase in the retinas of human subjects with diabetes mellitus. Am J Ophthalmol. 132:551–556. 2001. View Article : Google Scholar : PubMed/NCBI
27	Leal EC, Manivannan A, Hosoya K, Terasaki T, Cunha-Vaz J, Ambrósio AF and Forrester JV: Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 48:5257–5265. 2007. View Article : Google Scholar : PubMed/NCBI
28	Rosales MA, Silva KC, Duarte DA, de Oliveira MG, de Souza GF, Catharino RR, Ferreira MS, de Lopes Faria JB and de Lopes Faria JM: S-nitrosoglutathione inhibits inducible nitric oxide synthase upregulation by redox posttranslational modification in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci. 55:2921–2932. 2014. View Article : Google Scholar : PubMed/NCBI
29	Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y and Adamis AP: Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA. 96:10836–10841. 1999. View Article : Google Scholar : PubMed/NCBI
30	Zhang W, Liu H, Al-Shabrawey M, Caldwell RW and Caldwell RB: Inflammation and diabetic retinal microvascular complications. J Cardiovasc Dis Res. 2:96–103. 2011. View Article : Google Scholar : PubMed/NCBI